Asia-Pacific Advanced Wound Care Market - 2025-2033

Asia-Pacific Advanced Wound Care Market - 2025-2033

The Asia-Pacific advanced wound care market reached US$ 2.2 billion in 2024 and is expected to reach US$ 3.4 billion by 2033, growing at a CAGR of 5.1% during the forecast period 2025-2033.

Advanced wound care refers to specialized medical treatments, products and technologies designed to manage complex, non-healing, or chronic wounds that require more than basic wound care methods. These wounds may include diabetic foot ulcers, venous leg ulcers, pressure ulcers, surgical wounds, traumatic injuries, and burns. Unlike traditional wound care, which primarily focuses on cleaning and protecting wounds with simple dressings, advanced wound care involves the use of scientifically developed solutions that promote faster healing, manage infections, reduce pain, and improve the overall quality of life for patients.

The Asia-Pacific advanced wound care market is experiencing significant growth, driven by factors such as the increasing prevalence of chronic diseases, technological advancements and rising awareness and wound care initiatives in the region. For instance, in September 2024, HCAH, a leading provider of comprehensive out-of-hospital healthcare solutions in India, introduced a groundbreaking initiative aimed at accelerating patient recovery and improving healing processes. The company partnered with Aroa Biosurgery of New Zealand to tackle the challenges associated with bedsores and enhance patient care. With this partnership, HCAH launched the ""WOW (Warriors of Woundcare) Nurses"" programme, which focuses on preventing and treating bedsores effectively.

Market Dynamics: Drivers & Restraints

Rising aging population and prevalence of chronic diseases

The rising aging population and prevalence of chronic diseases are significantly driving the growth of the advanced wound care market in Asia-Pacific and are expected to drive the market over the forecast period. As people age, they are more susceptible to conditions that require advanced wound care, such as pressure ulcers due to prolonged immobility, diabetic foot ulcers due to complications from diabetes, and venous leg ulcers from poor circulation. Countries like Japan reported significant increases in the number of elderly patients requiring advanced wound management solutions.

For instance, according to the study conducted by the National Institute of Health, Of the 1126 participants, 113 (10%) had one or more pressure injuries. Overall, the estimated number of adults with pressure injuries in Goto (a city located on a remote rural archipelago in Japan) was 301.4. The prevalence rate of pressure injuries was 9.2 per 1000 population in adults aged ≥18 years, 20.3 in those aged ≥65 years, and 44.6 in those aged ≥80 years.

The high prevalence of diabetes across Asia, especially in countries like India and China, contributes significantly to the demand for advanced wound care. Chronic diabetic wounds, such as diabetic foot ulcers, are a major concern as they can lead to severe complications like amputations if not treated properly.

For instance, according to the World Health Organization, in India, an estimated 77 million people above the age of 18 years are suffering from diabetes (type 2) and nearly 25 million are prediabetics (at a higher risk of developing diabetes in the near future). More than 50% of people are unaware of their diabetic status. These lead to an increased need for advanced wound care products, such as advanced dressings and therapy devices, to manage chronic wounds effectively.

As the demand for effective wound management solutions grows, there is increased adoption of advanced wound care technologies, including bioengineered skin substitutes, negative pressure wound therapy (NPWT), and advanced dressings, which are becoming essential in treating these chronic wounds. For instance, in March 2022, Advanced Oxygen Therapy Inc. (AOTI) received the Chinese National Medical Products Administration (NMPA), commonly referred to as China FDA, approval for its unique cyclically pressurized Topical Wound Oxygen (TWO2) therapy.

Cultural and traditional preferences

Cultural and traditional preferences significantly hamper the growth of the Asia-Pacific advanced wound care market by influencing patients' and healthcare providers' choices in wound management. These cultural preferences often lead to the use of traditional methods over advanced, scientifically proven solutions.

In many Asian countries, there is a strong cultural inclination towards using herbal and natural remedies for health issues, including wound care. These treatments are perceived as more accessible, cost-effective, and culturally acceptable, often passed down through generations. For instance, in countries like India and China, traditional medicines, such as turmeric, neem, and aloe vera, are widely used to treat wounds due to their antiseptic and healing properties.

In rural areas of India, it’s common for families to use turmeric paste or neem leaves to cover wounds, believing that these natural substances promote faster healing and prevent infections. This preference for home remedies or traditional methods over modern, scientifically backed wound care solutions hinders the adoption of advanced wound care products that could offer better outcomes.

Cultural resistance plays a significant role in the slow uptake of advanced wound care solutions. In some communities, there is skepticism about the safety and efficacy of new technologies due to concerns about side effects or unfamiliarity. Traditional methods, deeply rooted in local culture, are often trusted more because they are seen as safe and proven over generations.

Segment Analysis

The Asia-Pacific advanced wound care market is segmented based on product type, wound type, end-user and region.

Wound Type:

The chronic wounds segment is expected to dominate the advanced wound care market share

The prevalence of diabetes in the Asia-Pacific region is among the highest in the world. In countries like India and China, the rising incidence of diabetes has led to a significant increase in diabetic foot ulcers, a common type of chronic wound. These ulcers are difficult to heal due to poor circulation, high blood sugar levels, and decreased immunity. The high prevalence of diabetes directly correlates with a higher incidence of diabetic foot ulcers, driving the demand for advanced wound care products.

Chronic wounds, such as diabetic foot ulcers, pressure ulcers and venous ulcers, are difficult to treat with conventional methods due to factors like bacterial contamination, lack of moisture balance, and impaired tissue regeneration. Advanced wound care products provide specialized solutions such as bioengineered skin substitutes, growth factors, and advanced dressings to manage these complex wounds effectively.

For instance, in October 2022, Healthium Medtech launched a new wound dressing portfolio Theruptor Novo for the management of chronic wounds like diabetic foot ulcers and leg ulcers. The MedTech company claims that with the launch of Theruptor Novo, Healthium strengthens its existing portfolio of patented products in the advanced wound dressing segment. Theruptor Novo is an anti-microbial and non-toxic wound dressing with technology patented in the US, India, EU and Canada.

The incidence of wounds is rising in the Asia-Pacific region, which increasing the demand for advanced wound care market. For instance, according to Treasury.gov, more than 420,000 Australians suffer from chronic wounds each year. Over 350,000 of them are 65 years or older. This means there are approximately 2,900 people and 2,400 seniors suffering from the painful burden in every federal electorate.

Competitive Landscape

The major Asia-Pacific players in the advanced wound care market include Coloplast Group, Axio Biosolutions Pvt Ltd, Lotus Surgicals Pvt Ltd, Medicare, Winner Medical Co., Ltd., 3M, Smith+Nephew, Cardinal Health, Mölnlycke Health Care AB, Convatec Inc. and among others.

Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Asia-Pacific advanced wound care market report delivers a detailed analysis with 39 key tables, more than 30 visually impactful figures, and 149 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.